Ibogaine Explained

Watchedfields:changed
Verifiedrevid:443866754
Synonyms:12-Methoxyibogamine
Iupac Name:(1R,15R,17S,18S)-17-ethyl-7-methoxy-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4(9),5,7-tetraene
Legal Au:S4
Legal Ca:Prescription only
Legal Ca Comment:[1]
Legal Nz:Prescription only
Legal Nz Comment:[2]
Legal Uk:PSA
Legal Un:Unscheduled
Legal Us:Schedule I
Routes Of Administration:Oral
Cas Number:83-74-9
Atc Prefix:None
Pubchem:197060
Chemspiderid:170667
Unii:3S814I130U
Chebi:5852
Chembl:1215855
C:20
H:26
N:2
O:1
Smiles:CC[C@H]1C[C@@H]2C[C@H]3c4[nH]c5ccc(OC)cc5c4CC[N@@](C2)[C@@H]13
Stdinchi:1S/C20H26N2O/c1-3-13-8-12-9-17-19-15(6-7-22(11-12)20(13)17)16-10-14(23-2)4-5-18(16)21-19/h4-5,10,12-13,17,20-21H,3,6-9,11H2,1-2H3/t12-,13+,17+,20+/m1/s1
Stdinchikey:HSIBGVUMFOSJPD-CFDPKNGZSA-N
Melting Point:152
Melting High:153

Ibogaine is an psychoactive indole alkaloid obtained either by extraction from plants in the family Apocynaceae such as Tabernanthe iboga, Voacanga africana, and Tabernaemontana undulata or by semi-synthesis from the precursor compound voacangine, another plant alkaloid. The total synthesis of ibogaine was described in 1956.[3] Structural elucidation by X-ray crystallography was completed in 1960.[4] [5] [6]

The psychoactivity of the root bark of the iboga tree, Tabernanthe iboga, one of the plants from which ibogaine is extracted, was first discovered by the Pygmy tribes of Central Africa, who passed the knowledge to the Bwiti tribe of Gabon. French explorers in turn learned of it from the Bwiti tribe and brought ibogaine back to Europe in 1899–1900, where it was subsequently marketed in France as a stimulant under the trade name Lambarène. Although ibogaine's anti-addictive properties were first widely promoted in 1962 by Howard Lotsof, its Western medical use predates that by at least a century.

During an eighteen year timeline, a total of 19 fatalities temporally associated with the ingestion of ibogaine were reported, from which six subjects died of acute heart failure or cardiopulmonary arrest. Its prohibition in many countries has slowed scientific research.[7] Various derivatives of ibogaine designed to lack psychedelic properties, such as 18-MC, are under preliminary research.

Psychoactive effects

Ibogaine is derived from the root of Tabernanthe iboga, a plant known to exhibit psychedelic effects in its users.[8] The experience of ibogaine occurs in two phases, termed the visionary phase and the introspection phase. The visionary phase has been described as oneirogenic, referring to the dreamlike nature of its psychedelic effects, and lasts for 4 to 6 hours. The second phase, the introspection phase, is responsible for the psychotherapeutic effects. It can allow people to conquer their fears and negative emotions. Ibogaine catalyzes an altered state of consciousness reminiscent of dreaming while fully conscious and aware so that memories, life experiences, and issues of trauma can be processed.[9]

Uses

Medical

Clinical studies of ibogaine to treat drug addiction began in the early 1990s, but concerns about cardiotoxicity terminated those studies.[10] A 2022 review indicated that severe adverse effects, including deaths, have impeded progress toward clinical adoption of ibogaine for use in opioid abstinence.[11] There is insufficient evidence to determine whether ibogaine is useful for treating addiction.[11] [12]

Adverse effects

Immediate adverse effects of ibogaine ingestion may include nausea, tremors leading to ataxia, headaches, and mental confusion. In long-term use, manic episodes may last for several days, possibly including insomnia, irritability, emotional instability, delusions, aggressive behavior, and thoughts of suicide. In the heart, ibogaine causes long QT syndrome at higher doses, apparently by blocking hERG potassium channels and slowing the heart rate.[13] Ibogaine should not be used during pregnancy or breastfeeding.

Ibogaine has potential for adverse interactions with other psychedelic agents and prescription drugs.

Death may occur with the use of ibogaine,[14] especially if consumed with opioids or in people with existing morbidities, such as cardiovascular disease or neurological disorders.

Neurotoxicity

Laboratory studies in rats indicate that high-dose ibogaine may cause degeneration of cerebellar Purkinje cells.[15] However, subsequent research found no evidence of neurotoxicity in a primate.[16]

In limited human research, neuropathological examination revealed no evidence of neuronal degenerative changes in a woman who had received four separate doses of ibogaine ranging between 10 and 30 mg⁄ kg over a 15-month interval. A published series of fatalities associated with ibogaine ingestion found no evidence for consistent neurotoxicity.[17]

Pharmacology

Pharmacodynamics

Site
Ibogaine Noribogaine
2,000–100,000 700–3,000
>100,000 5,000–25,000
2,000–4,000 600–1,000
5-HT2A16,000 >100,000
5-HT2C>10,000 >10,000
5-HT32,600 >100,000
σ12,500–9,000 11,000–15,000
σ290–400 5,000–19,000
1,000–3,000 6,000–15,000
20 1,500
500 40
2,000 2,000
Values are Ki (nM). The smaller the value, the
more strongly the drug binds to the site.

Ibogaine affects many different neurotransmitter systems simultaneously.[18]

Noribogaine is most potent as a serotonin reuptake inhibitor. It acts as a moderate κ-opioid receptor agonist[19] and weak μ-opioid receptor agonist[19] or weak partial agonist.[20] It is possible that the action of ibogaine at the kappa opioid receptor may indeed contribute significantly to the psychoactive effects attributed to ibogaine ingestion; Salvia divinorum, another plant recognized for its strong hallucinogenic properties, contains the chemical salvinorin A, which is a highly selective kappa opioid agonist. Noribogaine is more potent than ibogaine in rat drug discrimination assays when tested for the subjective effects of ibogaine.[21]

Pharmacokinetics

Ibogaine is metabolized in the human body by cytochrome P450 2D6 (CYP2D6) into noribogaine (more correctly, O-desmethylibogaine or 12-hydroxyibogamine). Both ibogaine and noribogaine have a plasma half-life of around two hours in rats,[22] although the half-life of noribogaine is slightly longer than that of the parent compound. It is proposed that ibogaine is deposited in fat and metabolized into noribogaine as it is released.[23] After ibogaine ingestion in humans, noribogaine shows higher plasma levels than ibogaine and is detected for a longer period of time than ibogaine.[24]

Chemistry

Ibogaine is a substituted tryptamine. It has two separate chiral centers, meaning that there are four different stereoisomers of ibogaine. These four isomers are difficult to resolve.[25]

Synthesis

One recent total synthesis[26] of ibogaine and related drugs starts with 2-iodo-4-methoxyaniline which is reacted with triethyl((4-(triethylsilyl)but-3-yn-1-yl)oxy)silane using palladium acetate in DMF to form 2-(triethylsilyl)-3-(2-((triethylsilyl)oxy)ethyl)-1H-indole. This is converted using N-iodosuccinamide and then fluoride to form 2-(2-iodo-1H-indol-3-yl)ethanol. This is treated with iodine, triphenyl phosphine, and imidazole to form 2-iodo-3-(2-iodoethyl)-1H-indole. Then, using 7-ethyl-2-azabicyclo[2.2.2]oct-5-ene and cesium carbonate in acetonitrile, the ibogaine precursor 7-ethyl-2-(2-(2-iodo-1H-indol-3-yl)ethyl)-2-azabicyclo[2.2.2]oct-5-ene is obtained. Using palladium acetate in DMF, the ibogaine is obtained. If the exo ethyl group on the 2-azabicyclo[2.2.2]octane system in ibogaine is replaced with an endo ethyl, then epiibogaine is formed.

Crystalline ibogaine hydrochloride is typically produced by semi-synthesis from voacangine in commercial laboratories.[27] [28] It can be prepared from voacangine through one-step demethoxycarbonylation process too.[29]

Derivatives

A synthetic derivative of ibogaine, 18-methoxycoronaridine (18-MC), is a selective α3β4 antagonist that was developed collaboratively by the neurologist Stanley D. Glick (Albany) and the chemist Martin E. Kuehne (Vermont).[30] This discovery was stimulated by earlier studies on other naturally occurring analogues of ibogaine, such as coronaridine and voacangine, that showed these compounds to have anti-addictive properties.[31] [32] More recently, non- and less-hallucinogenic analogs, tabernanthalog and ibogainalog, were engineered by scientists attempting to produce non-cardiotoxic ibogaine derivatives by removing the lipophilic isoquinuclidine ring. In animal models, both molecules failed to produce cardiac arrhythmias, and tabernanthalog failed to produce any head twitch response, suggesting psychedelic effects were absent.[33] [34]

Biosynthesis

Ibogaine biosynthesis begins with tryptophan undergoing enzymatic decarboxylation by tryptophan decarboxylase (TDC) to form a tryptamine. Secologanin, an iridoid synthesized from isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP), is reacted with tryptamine to make strictosidine. A glycosidic bond cleavage of strictosidine by strictosidine β-deglucosidase (SGD) produces a lactol. The lactol opens and produces an aldehyde, then condenses to form an iminium. Through isomerization and reduction by geissoschizine synthase 1 (GS1), 19E-geissoschizine is yielded. The indole is oxidized and the molecule undergoes intramolecular Mannich reaction and Grob fragmentation to form preakuammicine. Preakuammicine is highly unstable and therefore reduced to stemmadenine by oxidation-reduction reactions (REDOX 1 and REDOX 2). Stemmadine is acylated by stemmadine Ο-acetyltransferase (SAT) to yield stemmadine acetate. Through oxidation by precondylocarpine acetate synthase (PAS) and reduction by dihydroprecondylocarpine acetate synthase (DPAS), an enamine intermediate is formed. The intermediate undergoes fragmentation to produce an iminium that tautomerizes to yield dehydrosecodine. Coronaridine synthase (CorS) catalyzes the isomerization of dehydrosecodine and an unusual cycloaddition is completed. The iminium is reduced by DPAS and NADPH to form (-)-coronaridine.

There are two pathways (-)-coronaridine can take to become (-)-ibogaine. The first pathway begins with a P450 enzyme, ibogamine-10-hydroxylase (I10H), and methylation of noribogaine-10-Ο-methyltransferase (N10OMT) to produce (-)-voacangine. Polyneudridine aldehyde esterase-like 1 (PNAE1) and a spontaneous decarboxylation can convert (-)-voacangine to (-)-ibogaine. The second pathway consists of PNAE1 and the spontaneous decarboxylation occurring first to yield (-)-ibogamine, then the reaction of I10H-mediated hydroxylation and N10OMT-catalyzed O-methylation to produce (-)-ibogaine.[35]

Natural occurrence

Ibogaine occurs naturally in iboga root bark. Ibogaine is also available in a total alkaloid extract of the Tabernanthe iboga plant, which also contains all the other iboga alkaloids and thus has only about half the potency by weight of standardized ibogaine hydrochloride.[27]

History

The use of iboga in African spiritual ceremonies was first reported by French and Belgian explorers in the 19th century, beginning with the work of French naval physician and explorer of Gabon Marie-Théophile Griffon du Bellay.[36] The first botanical description of the Tabernanthe iboga plant was made in 1889. Ibogaine was first isolated from T. iboga in 1901 by Dybowski and Landrin[37] and independently by Haller and Heckel in the same year using T. iboga samples from Gabon. Complete synthesis of ibogaine was accomplished by G. Büchi in 1966.[38] Since then, several other synthesis methods have been developed.[39]

From the 1930s to 1960s, ibogaine was sold in France in the form of Lambarène, an extract of the Tabernanthe manii plant, and promoted as a mental and physical stimulant. The drug enjoyed some popularity among post-World War II athletes. Lambarène was withdrawn from the market in 1966 when the sale of ibogaine-containing products became illegal in France.[40]

In the late 1960s, the World Health Assembly classified ibogaine as a "substance likely to cause dependency or endanger human health"; the U.S. Food and Drug Administration (FDA) assigned it Schedule I classification, and the International Olympic Committee banned it as a potential doping agent.[41]

Anecdotal reports concerning ibogaine's effects appeared in the early 1960s.[42] Its anti-addictive properties were discovered accidentally by Howard Lotsof in 1962, at the age of 19, when he and five friends—all heroin addicts—noted subjective reduction of their craving and withdrawal symptoms while taking it.[43] Further anecdotal observation convinced Lotsof of its potential usefulness in treating substance addictions. He contracted with a Belgian company to produce ibogaine in tablet form for clinical trials in the Netherlands, and was awarded a United States patent for the product in 1985. The first objective, placebo-controlled evidence of ibogaine's ability to attenuate opioid withdrawal in rats was published by Dzoljic et al. in 1988.[44] Diminution of morphine self-administration was reported in preclinical studies by Glick et al. in 1991.[45] Cappendijk et al. demonstrated reduction in cocaine self-administration in rats in 1993,[46] and Rezvani reported reduced alcohol dependence in three strains of "alcohol-preferring" rats in 1995.[47]

As the use of ibogaine spread, its administration varied widely; some groups administered it systematically using well-developed methods and medical personnel, while others employed haphazard and possibly dangerous methodology. Lotsof and his colleagues, committed to the traditional administration of ibogaine, developed treatment regimens themselves. In 1992, Eric Taub brought ibogaine to an offshore location close to the United States, where he began providing treatments and popularizing its use.[48] In Costa Rica, Lex Kogan, another leading proponent, joined Taub in systematizing its administration. The two men established medically monitored treatment clinics in several countries.[49]

In 1981, an unnamed European manufacturer produced 44 kg of iboga extract. The entire stock was purchased by Carl Waltenburg, who distributed it under the name "Indra extract" and used it in 1982 to treat heroin addicts in the community of Christiania. Indra extract was available for sale over the Internet until 2006, when the Indra web presence disappeared. Various products are currently sold in a number of countries as "Indra extract", but it is unclear if any of them are derived from Waltenburg's original stock. Ibogaine and related indole compounds are susceptible to oxidation over time.[50] [51]

The National Institute on Drug Abuse (NIDA) began funding clinical studies of ibogaine in the United States in the early 1990s, but terminated the project in 1995.[52] Data demonstrating ibogaine's efficacy in attenuating opioid withdrawal in drug-dependent human subjects was published by Alper et al. in 1999.[53] A cohort of 33 patients were treated with 6 to 29 mg/kg of ibogaine; 25 displayed resolution of the signs of opioid withdrawal from 24 hours to 72 hours post-treatment, but one 24-year-old female, who received the highest dosage, died. Mash et al. (2000), using lower oral doses (10–12 mg/kg) in 27 patients, demonstrated significantly lower objective opiate withdrawal scores in heroin addicts 36 hours after treatment, with self-reports of decreased cocaine and opiate craving and alleviated depression symptoms. Many of these effects appeared sustainable over a one-month post-discharge follow-up.[54]

Society and culture

Legal status

, the legal status of ibogaine varies widely among countries, as it may be illegal to possess or use, may be legalized, may be decriminalized, or is under consideration for future legislation.[55]

In the United States, although some cities and states have decriminalized psychedelic chemicals, plants and mushrooms, ibogaine has had minimal legislation, and remains illegal under federal law, as of 2023.[55] [56] The US Drug Enforcement Administration enforces ibogaine as a Schedule I substance under the Controlled Substances Act.[57]

Treatment clinics

Ibogaine treatment clinics have emerged in Mexico, Bahamas, Canada, the Netherlands, South Africa, and New Zealand, all operating in what has been described as a "legal gray area".[58] [59] Costa Rica also has treatment centers.[49] Covert, illegal neighborhood clinics are known to exist in the United States, despite active DEA surveillance.[60] While clinical guidelines for ibogaine-assisted detoxification were released by the Global Ibogaine Therapy Alliance in 2015,[61] [62] addiction specialists warn that the treatment of drug dependence with ibogaine in non-medical settings, without expert supervision and unaccompanied by appropriate psychosocial care, can be dangerous — and, in approximately one case in 300, potentially fatal.[59]

Media

Documentary films

Print media

While in Wisconsin covering the primary campaign for the United States presidential election of 1972, gonzo journalist Hunter S. Thompson submitted a satirical article to Rolling Stone accusing Democratic Party candidate Edmund Muskie of being addicted to ibogaine. Many readers, and even other journalists, did not realize that the Rolling Stone piece was facetious. The ibogaine assertion, which was completely unfounded, did significant damage to Muskie's reputation, and was cited as a factor in his loss of the nomination to George McGovern.[66] Thompson later said he was surprised that anyone believed it.[67] The article is included in Thompson's post-election anthology, Fear and Loathing on the Campaign Trail '72 (1973).[68]

Author and Yippie Dana Beal co-wrote the 1997 book The Ibogaine Story.[69]

American author Daniel Pinchbeck wrote about his own experience of ibogaine in his book Breaking Open the Head (2002),[70] and in a 2003 article for The Guardian titled "Ten years of therapy in one night".[71]

Author and musician Geoff Rickly based his debut novel Someone Who Isn't Me on his real-life experiences with heroin addiction and an ibogaine clinic in Mexico.[72]

Television drama

Ibogaine factors into the stories of these episodes from television drama series:

Radio

Research

Addiction treatment

The most-studied therapeutic effect of ibogaine is the possible reduction or elimination of addiction to opioids. Research suggests that ibogaine may be useful in treating dependence on other substances such as alcohol, methamphetamine, and nicotine, and may affect compulsive behavioral patterns not involving substance abuse or chemical dependence. Researchers note that there remains a "need for systematic investigation in a conventional clinical research setting."[42]

Many users of ibogaine report experiencing visual phenomena during a waking dream state, such as instructive replays of life events that led to their addiction, while others report therapeutic shamanic visions that help them conquer the fears and negative emotions that might drive their addiction. It is proposed that intensive counseling, therapy, and aftercare during the interruption period following treatment is of significant value. Some individuals require a second or third treatment session with ibogaine over the course of 12 to 18 months. A minority of individuals relapse completely into opiate addiction within days or weeks.[74]

Psychotherapy

Ibogaine was used as an adjunct to psychotherapy by Claudio Naranjo, documented in his book The Healing Journey.[75] He was awarded patent in 1974.

See also

Notes and References

  1. Web site: Health Canada . Government of Canada, Health. Notice - Prescription Drug List (PDL): Multiple additions. en. 12 May 2017.
  2. Galea S, Lorusso M, Newcombe D, Walters C, Williman J, Wheeler A . Ibogaine--be informed before you promote or prescribe . Journal of Primary Health Care . 3 . 1 . 86–7 . March 2011 . 21359272 . 4 December 2015 . Goodyear-Smith F .
  3. US. 2813873. patent. Derivatives of the ibogaine alkaloids. 9 October 1956. 19 November 1957. Morrice-Marie Janot. Robert Goutarel. Les Laboratoires Gobey.
  4. Soriano-García M . Structure of ibogaine . . 1992 . 48 . 11 . 2055–2057 . 10.1107/S0108270192002786 . 1992AcCrC..48.2055S .
  5. Soriano-García M, Walls F, Rodríguez A, Celis IL . Crystal and molecular structure of ibogamine: An alkaloid from Stemmadenia galeottiana . 10.1007/BF01181911 . Journal of Crystallographic and Spectroscopic Research . 18 . 2 . 197–206 . 1988 . 97519993 .
  6. Arai G, Coppola J, Jeffrey GA . 10.1107/S0365110X60001369 . The structure of ibogaine . Acta Crystallographica . 13 . 7 . 553–564 . 1960 . 1960AcCry..13..553A .
  7. Alper KR, Lotsof HS, Kaplan CD . The ibogaine medical subculture . Journal of Ethnopharmacology . 115 . 1 . 9–24 . January 2008 . 18029124 . 10.1016/j.jep.2007.08.034 . https://web.archive.org/web/20080206110946/http://www.ibogaine.org/subculture.html . dead . 6 February 2008.
  8. Alper KR, Beal D, Kaplan CD . A contemporary history of ibogaine in the United States and Europe . The Alkaloids. Chemistry and Biology . 56 . 249–81 . 2001 . 11705112 . Academic Press . 10.1016/S0099-9598(01)56018-6 . 21 September 2013 . https://web.archive.org/web/20160304031149/http://www.ibogaine.desk.nl/ch14.pdf . 4 March 2016 . dead . 978-0-12-469556-6 . 119074996 .
  9. Book: Practical Skills and Clinical Management of Alcoholism & Drug Addiction . Obembe SB . 88 . 9780123985187 . 2012 . Elsevier . 802345585 .
  10. Brown TK . Ibogaine in the treatment of substance dependence . Current Drug Abuse Reviews . 6 . 1 . 3–16 . March 2013 . 23627782 . 10.2174/15672050113109990001 .
  11. Köck P, Froelich K, Walter M, Lang U, Dürsteler KM . A systematic literature review of clinical trials and therapeutic applications of ibogaine . Journal of Substance Abuse Treatment . 138 . 108717 . July 2022 . 35012793 . 10.1016/j.jsat.2021.108717 .
  12. Vastag B . Addiction research. Ibogaine therapy: a 'vast, uncontrolled experiment' . Science . 308 . 5720 . 345–6 . April 2005 . 15831735 . 10.1126/science.308.5720.345 . 70642078 .
  13. Alper K, Bai R, Liu N, Fowler SJ, Huang XP, Priori SG, Ruan Y . hERG Blockade by Iboga Alkaloids . Cardiovascular Toxicology . 16 . 1 . 14–22 . January 2016 . 25636206 . 10.1007/s12012-015-9311-5 . 16071274 .
  14. Koenig X, Hilber K . The anti-addiction drug ibogaine and the heart: a delicate relation . Molecules. 20 . 2 . 2208–28 . January 2015 . 25642835 . 4382526 . 10.3390/molecules20022208. free.
  15. O'Hearn E, Molliver ME . Degeneration of Purkinje cells in parasagittal zones of the cerebellar vermis after treatment with ibogaine or harmaline . Neuroscience . 55 . 2 . 303–10 . July 1993 . 8377927 . 10.1016/0306-4522(93)90500-f . 25273690 .
  16. Mash DC, Kovera CA, Buck BE, Norenberg MD, Shapshak P, Hearn WL, Sanchez-Ramos J. 3 . Medication development of ibogaine as a pharmacotherapy for drug dependence . Annals of the New York Academy of Sciences . 844 . 1 . 274–92 . May 1998 . 9668685 . 10.1111/j.1749-6632.1998.tb08242.x . 1998NYASA.844..274M . 22068338 .
  17. Alper KR, Stajić M, Gill JR . Fatalities temporally associated with the ingestion of ibogaine . Journal of Forensic Sciences . 57 . 2 . 398–412 . March 2012 . 22268458 . 10.1111/j.1556-4029.2011.02008.x . 6670557 .
  18. Alper KR . Alper KR, Glick SD . The Alkaloids: Chemistry and Biology . Academic . San Diego . 2001 . 1–38 . 978-0-12-469556-6 . 1099-4831 . 119074989 . 56 . Ibogaine: A Review . dead . https://web.archive.org/web/20070927225940/http://ibogaine.org/ch01.pdf . 27 September 2007.
  19. Maillet EL, Milon N, Heghinian MD, Fishback J, Schürer SC, Garamszegi N, Mash DC . Noribogaine is a G-protein biased κ-opioid receptor agonist . Neuropharmacology . 99 . December 2015 . 675–88 . December 2015 . 26302653 . 10.1016/j.neuropharm.2015.08.032 . free . 0028-3908 . 5921346571.
  20. Antonio T, Childers SR, Rothman RB, Dersch CM, King C, Kuehne M, Bornmann WG, Eshleman AJ, Janowsky A, Simon ER, Reith ME, Alper K . Effect of Iboga alkaloids on µ-opioid receptor-coupled G protein activation . PLOS ONE . 8 . 10 . e77262 . 2013 . 24204784 . 3818563 . 10.1371/journal.pone.0077262 . 2013PLoSO...877262A . free . 1932-6203 . 5534534188.
  21. Zubaran C, Shoaib M, Stolerman IP, Pablo J, Mash DC . Noribogaine generalization to the ibogaine stimulus: correlation with noribogaine concentration in rat brain . Neuropsychopharmacology . 21 . 1 . 119–26 . July 1999 . 10379526 . 10.1016/S0893-133X(99)00003-2 . free . 1740-634X . 9523107895.
  22. Baumann MH, Rothman RB, Pablo JP, Mash DC . In vivo neurobiological effects of ibogaine and its O-desmethyl metabolite, 12-hydroxyibogamine (noribogaine), in rats . The Journal of Pharmacology and Experimental Therapeutics . 297 . 2 . 531–9 . May 2001 . 11303040 . 0022-3565 . 118935157.
  23. Hough LB, Bagal AA, Glick SD . Pharmacokinetic characterization of the indole alkaloid ibogaine in rats . Methods and Findings in Experimental and Clinical Pharmacology . 22 . 2 . 77–81 . March 2000 . 10849889 . 10.1358/mf.2000.22.2.796066 . 0379-0355 . 118905358.
  24. Mash DC, Kovera CA, Pablo J, Tyndale RF, Ervin FD, Williams IC, Singleton EG, Mayor M . Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures . Annals of the New York Academy of Sciences . 914 . 1 . 394–401 . September 2000 . 11085338 . 10.1111/j.1749-6632.2000.tb05213.x . 10.1.1.598.8242 . 2000NYASA.914..394M . 33436971 . 0077-8923 . 117596065.
  25. Book: Shulgin A, Shulgin A . IBOGAINE; 12-METHOXYIBOGAMINE . https://archive.org/details/tihkalcontinuati0000shul/page/486/mode/2up . registration . Tihkal: the continuation . registration . Internet Archive . Transform Press . Berkeley, CA . 1997 . 978-0-9630096-9-2 . 1360062118 . 487–490.
  26. Jana GK, Sinha S . 10.1016/j.tet.2012.06.027 . Total synthesis of ibogaine, epiibogaine and their analogues . Tetrahedron . 68 . 35 . 7155–7165 . 2012 . 0040-4020 . 5901603422.
  27. Jenks CW . Extraction studies of Tabernanthe iboga and Voacanga africana . Natural Product Letters . 16 . 1 . 71–6 . February 2002 . 11942686 . 10.1080/1057563029001/4881 . 23390825 . 1057-5634 . 4803437833.
  28. Web site: Voacanga Extraction Manual: Phase 4: Production and Purification of Ibogaine. www.puzzlepiece.org. 4 December 2015.
  29. Krengel F, Mijangos MV, Reyes-Lezama M, Reyes-Chilpa R . Extraction and Conversion Studies of the Antiaddictive Alkaloids Coronaridine, Ibogamine, Voacangine, and Ibogaine from Two Mexican Tabernaemontana Species (Apocynaceae) . Chemistry & Biodiversity . 16 . 7 . e1900175 . July 2019 . 31095891 . 10.1002/cbdv.201900175 . 157058497 .
  30. Pace CJ, Glick SD, Maisonneuve IM, He LW, Jokiel PA, Kuehne ME, Fleck MW . Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration . European Journal of Pharmacology . 492 . 2–3 . 159–67 . May 2004 . 15178360 . 10.1016/j.ejphar.2004.03.062 .
  31. Glick SD, Kuehne ME, Raucci J, Wilson TE, Larson D, Keller RW, Carlson JN . Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum . Brain Research . 657 . 1–2 . 14–22 . September 1994 . 7820611 . 10.1016/0006-8993(94)90948-2 . 1940631 .
  32. Antiaddictive indole alkaloids in Ervatamia yunnanensis and their bioactivity . Hua T . Academic Journal of Second Military Medical University . 28 January 2006 . 15 August 2012 . 13 February 2012 . https://web.archive.org/web/20120213104620/http://www.shvoong.com/medicine-and-health/1611478-antiaddictive-indole-alkaloids-ervatamia-yunnanensis/ . dead .
  33. Cameron LP, Tombari RJ, Lu J, Pell AJ, Hurley ZQ, Ehinger Y, Vargas MV, McCarroll MN, Taylor JC, Myers-Turnbull D, Liu T, Yaghoobi B, Laskowski LJ, Anderson EI, Zhang G, Viswanathan J, Brown BM, Tjia M, Dunlap LE, Rabow ZT, Fiehn O, Wulff H, McCorvy JD, Lein PJ, Kokel D, Ron D, Peters J, Zuo Y, Olson DE . 6 . A non-hallucinogenic psychedelic analogue with therapeutic potential . Nature . 589 . 7842 . 474–479 . January 2021 . 33299186 . 7874389 . 10.1038/s41586-020-3008-z . 2021Natur.589..474C .
  34. News: Hamilton J . 2020-12-09. Progress Toward A Safer Psychedelic Drug To Treat Depression And Addiction . 2020-12-12. NPR.org. en.
  35. Iyer RN, Favela D, Zhang G, Olson DE . The iboga enigma: the chemistry and neuropharmacology of iboga alkaloids and related analogs . Natural Product Reports . 38 . 2 . 307–329 . March 2021 . 32794540 . 7882011 . 10.1039/D0NP00033G .
  36. Web site: Marie Théophile GRIFFON du BELLAY (1829–1908) . ecole.nav.traditions.free.fr . 2023-02-05 . https://web.archive.org/web/20230306023457/https://ecole.nav.traditions.free.fr/officiers_griffon_theophile.htm . 2023-03-06 . dead.
  37. Dybowski J, Landrin E . 1901 . PLANT CHEMISTRY. Concerning Iboga, its excitement-producing properties, its composition, and the new alkaloid it contains, ibogaine . C. R. Acad. Sci. . 133 . 748 . 20 May 2013 . https://web.archive.org/web/20130710095016/http://www.ibogaine.desk.nl/dybowski.html . 10 July 2013 . dead .
  38. Büchi G, Coffen DL, Kocsis K, Sonnet PE, Ziegler FE . 1966 . The Total Synthesis of Iboga Alkaloids . J. Am. Chem. Soc. . 88 . 13 . 3099–3109 . 10.1021/ja00965a039.
  39. 1999 . Ph.D. . https://web.archive.org/web/20120729170535/http://e-collection.library.ethz.ch/view/eth:23217 . 29 July 2012 . Frauenfelder C . 24 . dead .
  40. Freedlander J . Ibogaine: a Comprehensive Literature Review . 1 . 2003 . Journal of Drug Addiction, Education, and Eradication . Nova Science Publishers . 609715451 . 1546-6965 . 79–98 . 2024-07-23 . ibogaine.mindvox.com.
  41. http://iceers.org/docs/science/iboga/ICEERS2012_Ibogaine_literature_compilation.pdf Ibogaine – Scientific Literature Overview
  42. Alper KR, Lotsof HS, Frenken GM, Luciano DJ, Bastiaans J . Treatment of acute opioid withdrawal with ibogaine . The American Journal on Addictions . 8 . 3 . 234–42 . 1999 . 10506904 . 10.1080/105504999305848 . dead . https://web.archive.org/web/20020126202626/http://www.ibogaine.desk.nl/p234_s.pdf . 26 January 2002 .
  43. News: Howard Lotsof Dies at 66; Saw Drug Cure in a Plant. The New York Times. 17 February 2010. 11 June 2015. 0362-4331. Hevesi D .
  44. Dzoljic ED, Kaplan CD, Dzoljic MR . Effect of ibogaine on naloxone-precipitated withdrawal syndrome in chronic morphine-dependent rats . Archives Internationales de Pharmacodynamie et de Therapie . 294 . 64–70 . 1988 . 3233054 .
  45. Glick SD, Rossman K, Steindorf S, Maisonneuve IM, Carlson JN . Effects and aftereffects of ibogaine on morphine self-administration in rats . European Journal of Pharmacology . 195 . 3 . 341–5 . April 1991 . 1868880 . 10.1016/0014-2999(91)90474-5 .
  46. Cappendijk SL, Dzoljic MR . Inhibitory effects of ibogaine on cocaine self-administration in rats . European Journal of Pharmacology . 241 . 2–3 . 261–5 . September 1993 . 8243561 . 10.1016/0014-2999(93)90212-Z .
  47. Rezvani AH, Overstreet DH, Lee YW . Attenuation of alcohol intake by ibogaine in three strains of alcohol-preferring rats . Pharmacology, Biochemistry, and Behavior . 52 . 3 . 615–20 . November 1995 . 8545483 . 10.1016/0091-3057(95)00152-M . 38567079 .
  48. Web site: A Home for Ibogaine in Barcelona. The Huffington Post. 11 June 2015. 17 July 2007.
  49. Web site: Costa Rican Center a Leader in Alternative Ibogaine Therapy . Treatment Magazine . 11 September 2012 . 11 June 2015. https://web.archive.org/web/20131203074414/http://www.treatmentmagazine.com/newswires/307-costa-rican-center-a-leader-in-alernative-ibogaine-therapy.html. December 3, 2013.
  50. Kontrimaviciūte V, Mathieu O, Mathieu-Daudé JC, Vainauskas P, Casper T, Baccino E, Bressolle FM . Distribution of ibogaine and noribogaine in a man following a poisoning involving root bark of the Tabernanthe iboga shrub . Journal of Analytical Toxicology . 30 . 7 . 434–40 . September 2006 . 16959135 . 10.1093/jat/30.7.434 . free .
  51. Book: The Alkaloids: Chemistry and Physiology. Taylor WI . 1965. The Iboga and Voacanga Alkaloids. 203, 207–208. http://www.puzzlepiece.org/ibogaine/literature/taylor1965.pdf.
  52. Web site: A Non-Profit Approach to Developing Ibogaine into an FDA-Approved Medication . ppt . 16 August 2012 . Doblin R . dead . https://web.archive.org/web/20121030115002/http://www.ibogaine.desk.nl/ibogaineresearch.ppt . 30 October 2012.
  53. Alper KR, Lotsof HS, Frenken GM, Luciano DJ, Bastiaans J . Treatment of acute opioid withdrawal with ibogaine . The American Journal on Addictions . 8 . 3 . 234–42 . 1999 . 10506904 . 10.1080/105504999305848 . dead . https://web.archive.org/web/20020126202626/http://www.ibogaine.desk.nl/p234_s.pdf . 2002-01-26 .
  54. Mash DC, Kovera CA, Pablo J, Tyndale RF, Ervin FD, Williams IC, Singleton EG, Mayor M . 6 . Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures . Annals of the New York Academy of Sciences . 914 . 1 . 394–401 . September 2000 . 11085338 . 10.1111/j.1749-6632.2000.tb05213.x . 10.1.1.598.8242 . 2000NYASA.914..394M . 33436971 . 6 July 2006 . https://web.archive.org/web/20070303181654/http://ibogaine.mindvox.com/Articles/Mash-01.pdf . 3 March 2007 . dead .
  55. News: Chesak J. What psychedelics legalisation and decriminalisation looks like around the world. 22 March 2024 . BBC . 22 March 2024.
  56. Siegel JS, Daily JE, Perry DA, Nicol GE . Psychedelic Drug Legislative Reform and Legalization in the United States . JAMA Psychiatry . 80 . 1 . 77–83 . January 2023 . 36477830 . 10069558 . 10.1001/jamapsychiatry.2022.4101.
  57. Web site: Iboga (ibogaine). Drugs.com . 22 March 2024 . 21 April 2023.
  58. Web site: Hegarty S . Can a hallucinogen from Africa cure addiction? . BBC News . 2012-04-10 . 2024-07-24.
  59. Web site: Ibogaine Therapy . Multidisciplinary Association for Psychedelic Studies - MAPS . 1979-04-19 . 2024-07-24.
  60. Web site: Hunter A . Busted for Iboga . The Village Voice . 2005-12-13 . 2024-07-24.
  61. >Web site: Clinical Guidelines for Ibogaine-Assisted Detoxification . IBOGAINE SAFETY GUIDELINES . 2020-10-28 . 2024-07-24.
  62. Web site: The Global Ibogaine Therapy Alliance (GITA). The Global Ibogaine Therapy Alliance. 14 January 2016. 25 January 2016. https://web.archive.org/web/20160125093313/http://www.ibogainealliance.org/. dead.
  63. Web site: Detox or Die . One Life . BFI . 2004-06-08 . 2024-07-24.
  64. Web site: Tripping in Amsterdam . . 23 June 2008 . Current.com . 7 April 2013 . https://web.archive.org/web/20121011061542/http://current.com/green/89043771_tripping-in-amsterdam.htm . 11 October 2012 . dead .
  65. Web site: Home - DOSED - It's Not Magic, It's Medicine. DOSED. 1 June 2020.
  66. Web site: Online NewsHour: Remembering Ed Muskie . pbs.org . 1999-02-03 . http://web.archive.org/web/19990427124548/http://www.pbs.org/newshour/bb/remember/muskie_3-26.html . 1999-04-27 . dead.
  67. Gibney A . Alex Gibney . 2008 . . Motion picture . 259718859.
  68. Book: 1973 . Fear and Loathing on the Campaign Trail '72 . 978-0-87932-053-9 . 636410 . 150–54 . Straight Arrow Books .
  69. Book: Beal D, De Rienzo P . The Ibogaine Story: Report on the Staten Island Project . Autonomedia . 1997 . 1570270295 .
  70. Book: Pinchbeck D . Daniel Pinchbeck . Breaking Open the Head: A Psychedelic Journey into the Heart of Contemporary Shamanism . Broadway Books . 2002 . 9780767907422 . 50601753.
  71. News: Pinchbeck D . Daniel Pinchbeck . 19 September 2003 . Ten years of therapy in one night . . London . 15 December 2013.
  72. Book: Rickly G . Geoff Rickly . Someone Who Isn't Me .
  73. Sink or Swim. Act Two. I'm Not A Doctor But I Play One At The Holiday Inn. . 17 August 2015 . This American Life . This American Life . Olkowski L, Kay T . 1 December 2006 . 321 . 16 .
  74. Lotsof HS . 1995 . Ibogaine in the Treatment of Chemical Dependence Disorders: Clinical Perspectives . MAPS Bulletin . 3 . 19–26 . dead . https://web.archive.org/web/19970122031859/http://www.ibogaine.desk.nl/clin-perspectives.html . 22 January 1997. dmy-all.
  75. Book: Naranjo C . The healing journey: new approaches to consciousness . Pantheon Books . New York . 1973 . 978-0-394-48826-4 . http://www.ibogaine.desk.nl/naranjo.html . V, Ibogaine: Fantasy and Reality . 197–231 . 15 August 2012 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Ibogaine".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.